DAIICHI SANKYO, INC.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1900
- Registration Number
- NCT00185133
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT00185068
The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
Phase 4
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 20
- Registration Number
- NCT00185055
Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 152
- Registration Number
- NCT00185120
- Locations
- 🇺🇸
Memorial Research Medical Center, Long Beach, California, United States
🇺🇸National Research Institute, Los Angeles, California, United States
🇺🇸Clinical Trials Research, Roseville, California, United States
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
Phase 2
Completed
- Conditions
- Coronary Heart Disease
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 534
- Registration Number
- NCT00185042
Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol
Phase 4
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 45
- Registration Number
- NCT00185107
- Locations
- 🇺🇸
Scripps Clinic, San Diego, California, United States
🇺🇸Renstar Medical Research, Ocala, Florida, United States
🇺🇸Radiant Research, Edina, Minnesota, United States
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
Phase 4
Completed
- Conditions
- Metabolic SyndromeHypertensionInsulin Resistance
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-12-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 60
- Registration Number
- NCT00185094
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 362
- Registration Number
- NCT00151775
WelChol® and Insulin in Treating Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 260
- Registration Number
- NCT00151749
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
Phase 2
Terminated
- Conditions
- AtherosclerosisHeterozygous Familial Hypercholesterolemia
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 796
- Registration Number
- NCT00151788